Table of Contents

company-logo

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Corvus Pharmaceuticals Dividend Announcement

• Corvus Pharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Corvus Pharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Corvus Pharmaceuticals Dividend History

Corvus Pharmaceuticals Dividend Yield

Corvus Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Corvus Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Corvus Pharmaceuticals Financial Ratios

P/E ratio-9.57
PEG ratio0.52
P/B ratio43.81
ROE-167.55%
Payout ratio0.00%
Current ratio0.92
Quick ratio0.92
Cash Ratio0.10

Corvus Pharmaceuticals Dividend FAQ

Does Corvus Pharmaceuticals stock pay dividends?
Corvus Pharmaceuticals does not currently pay dividends to its shareholders.
Has Corvus Pharmaceuticals ever paid a dividend?
No, Corvus Pharmaceuticals has no a history of paying dividends to its shareholders. Corvus Pharmaceuticals is not known for its dividend payments.
Why doesn't Corvus Pharmaceuticals pay dividends?
There are several potential reasons why Corvus Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Corvus Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Corvus Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Corvus Pharmaceuticals a dividend aristocrat?
Corvus Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Corvus Pharmaceuticals a dividend king?
Corvus Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Corvus Pharmaceuticals a dividend stock?
No, Corvus Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Corvus Pharmaceuticals stocks?
To buy Corvus Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Corvus Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.